Shield Therapeutics plc

LSE STX.L

Shield Therapeutics plc Net Income Margin for the year ending December 31, 2023: -254.44%

Shield Therapeutics plc Net Income Margin is -254.44% for the year ending December 31, 2023, a 71.90% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Shield Therapeutics plc Net Income Margin for the year ending December 31, 2022 was -905.40%, a 28.87% change year over year.
Shield Therapeutics plc Net Income Margin for the year ending December 31, 2021 was -1,272.94%, a -4,927.40% change year over year.
Shield Therapeutics plc Net Income Margin for the year ending December 31, 2020 was -25.32%, a 97.93% change year over year.
Shield Therapeutics plc Net Income Margin for the year ending December 31, 2019 was -1,223.92%, a -8,005.58% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

LSE: STX.L

Shield Therapeutics plc

CEO	Dr. Christian Schweiger M.D., Ph.D.
IPO Date	Feb. 26, 2016
Location	United Kingdom
Headquarters	Northern Design Centre
Employees	73
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Fertilizers Non-Alcoholic Beverages Personal Care

Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Key trends

Past 5 years